疑似急性冠脉综合征患者换用高敏肌钙蛋白后的1年死亡结局
结果显示换用hs-cTnI与30天死亡率(aHR 0.88,95%CI 0.82-0.95)和1年死亡率(aHR 0.90,95%CI 0.85-0.94)降低相关,新发心肌梗死比例无显著差异。
要点
- 换用hs-cTnI与30天及1年死亡率降低相关。
- 新发心肌梗死诊断比例无显著差异,不稳定心绞痛诊断减少。
- 非换用地区死亡率无统计学差异,支持结果稳健性。
核心结论
- 在疑似ACS急诊人群中,使用hs-cTnI检测与1年死亡率降低相关。
研究设计与样本
- 前期所有医院使用传统肌钙蛋白检测,后期4家医院换用hs-cTnI(性别特异性第99百分位阈值),其余未换用。
- 结局通过关联行政数据确定,采用Kaplan-Meier和Cox回归分析比较。
主要发现
- 换用hs-cTnI后新发心肌梗死比例无显著差异(3.9% vs 4.2%,p=0.08)。
- 换用hs-cTnI后不稳定心绞痛诊断比例降低(1.5% vs 2.5%,p<0.0001)。
- 换用hs-cTnI与30天死亡率降低相关(调整HR 0.88,95%CI 0.82-0.95)。
- 换用hs-cTnI与1年死亡率降低相关(调整HR 0.90,95%CI 0.85-0.94)。
- 非换用地区新发心肌梗死率稳定,不稳定心绞痛诊断增加,相应aHR无统计学差异。
临床怎么用
- 急诊疑似ACS患者采用hs-cTnI及性别特异性第99百分位阈值可能改善1年生存。
- 换用hs-cTnI后需关注不稳定心绞痛诊断比例下降的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching from a conventional to a high-sensitivity cardiac troponin (hs-cTn) assay enables detection of smaller amounts of myocardial damage, but the clinical benefit is unclear. We investigated whether switching to a hs-cTnI assay with a sex-specific 99th centile diagnostic threshold was associated with lower 1-year death or new myocardial infarction (MI) in patients with suspected acute coronary syndrome (ACS). METHODS: This pre-post study included nine tertiary hospitals in Australia. During the pre-hs-cTn period, all hospitals used conventional troponin assays, and during the postperiod, four switched to using hs-cTnI. Participants were ≥20 years old and presenting to emergency departments (EDs) with suspected ACS between March 2011 and November 2015. Outcomes were determined using linked administrative data and compared using Kaplan-Meier and Cox regression analyses. RESULTS: We identified 179 681 consecutive patients (62 (SD 19) years, 47% women), 87 019 (48%) during the preperiod, and 92 662 (52%) during the postperiod. Following the switch to hs-TnI, the proportion of patients diagnosed with new MI was not significantly different (3.9% postperiod vs 4.2% preperiod; p=0.08) while diagnoses of unstable angina were lower (1.5% postperiod vs 2.5% preperiod; p<0.0001). In non-switching jurisdictions, rates of new MI remained stable, while diagnoses of unstable angina increased. Switching to hs-cTnI assay was associated with lower mortality at 30 days (adjusted HR 0.88 (0.82, 0.95)) and 1 year (aHR 0.90 (0.85, 0.94)). The corresponding aHRs for non-switching jurisdictions were not statistically different. CONCLUSION: The use of an hs-cTnI assay in an ED population with suspected ACS was associated with lower mortality at 1 year.
引用
- Hickling, Sanfilippo, Cullen, et al. Transitioning to high-sensitivity troponin: 1-year mortality outcomes in patients with suspected acute coronary syndrome presenting to emergency departments. Heart. 2025. PMID: 39819623. doi:10.1136/heartjnl-2024-324959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。